[English]  [Pусский]  [中文]  
 
ctt-journal > Tangen et al. (Abstract)

Tangen et al. (Abstract)

Cellular Therapy and Transplantation (CTT), Vol. 3, No. 12
doi: 10.3205/ctt-2011-No12-abstract92

© The Authors. This abstract is provided under the following license: Creative Commons Attribution 3.0 Unported

Abstract accepted for "5th Raisa Gorbacheva Memorial Meeting Hematopoietic Stem Cell Transplantation in Children and Adults", Saint Petersburg, Russia, September 18–20, 2011

Preliminary Program

Contribute a comment

The medical mushroom Agaricus blazeii Murill as adjuvant treatment in patients with multiple myeloma receiving high dose chemotherapy with autologous stem cell support. Preliminary results from a pilot study

Jon-Magnus Tangen1 and  Geir Hetland2

1Department of Hematology, Oslo University Hospital, Oslo, Norway; 2Department of Cell Therapy, Oslo University Hospital, Oslo, Norway

Correspondence: Dr. Jon Magnus Tangen, Medical Clinic.Hematology Department, Ullevål Hospital. N-0407 Oslo, Norway, E-mail: jmtangen@spam is badyahoo.com

Abstract

The edible mushroom Agaricus blazeii Murill (AbM) grows naturally in a rural area outside Sao Paulo in Brazil. According to local legend this mushroom has a treatment effect against a number of diseases, and in particular against infection and cancer. AbM is grown industrially in Japan, and an extract of this mushroom is sold on the health food market worldwide. AbM has been the subject of extensive scientific investigations and its immuno-stimulating properties in vitro are well documented. An antitumor effect has also been reported, both from in vitro and from preclinical studies. Furthermore, increased NK cell activity and improved quality of life was reported in a clinical study where patients with gynecological cancer receiving chemotherapy were given adjuvant treatment with AbM.

Pilot study in patients with multiple myeloma:

Thirty-three patients with multiple myeloma scheduled to receive high-dose melphalan and autologus stem cell support were randomized to receive either AbM or a placebo (60 ml a day per os) in a blinded fashion. The intake of the study product started on the day of stem cell mobilizing treatment and continued until the end of aplasia after high-dose melphalan and stem cell support, i.e., a period of 6–7 weeks.

Primary endpoints of the study are expression of genes involved in the innate immunological cancer defense as measured by affymetrix, blood levels of cytokines and chemokines as measured by luminex, and NK activity in peripheral blood as measured by flow cytometry.
Secondary endpoints are quality of life, treatment response, infectious complications, and number of days with intravenous antibiotic treatment.

Keywords: Agaricus blazei Murill, multiple myeloma, gene expression, cytokines, natural killer cell, infection